drugset / Trial / NCT03971357

Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration

NCT03971357 ↗

Phase 2/3 Terminated 19 enrolled Price Vision Group
RandomizedParallel-groupTriple-blindTreatment

Summary

Subjects with Fuchs dystrophy will be randomized to use either netarsudil or placebo eye drops to determine if the use of netarsudil accelerates migration of host peripheral corneal endothelial cells to restore the central endothelial cell layer.

Timeline

Start
2019-07-22
Primary completion
2021-08-26
Completion
2021-08-26

Outcome

Outcome not reported

Stopped: “variance of outcome measures was substantially greater than anticipated in the statistical plan”

Drugs

EvaluationDrugModalityDoseRoute
Subject Netarsudil Small molecule 0.02 % Topical